Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02498613
Title A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung small cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

pancreatic adenocarcinoma

Therapies

Cediranib + Olaparib

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.